medwireNews: The US FDA has approved intravenous immunoglobulin (IVIG) for the treatment of dermatomyositis in adults.
Previously approved for chronic immune thrombocytopenic purpura, IVIG may now be used for dermatomyositis at a dose of 2 g/kg divided into equal doses given over 2–5 consecutive days once every 4 weeks.
This approval is based on results from the phase 3 ProDERM trial, which demonstrated significantly higher treatment response rates among patients with active dermatomyositis who were treated with IVIG versus placebo.
The label for IVIG contains a boxed warning for thrombosis, renal dysfunction, and acute renal failure.
medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2021 Springer Healthcare Ltd, part of the Springer Nature Group